Jianfan Bio: Announcement on applying for a comprehensive credit line from the bank
Securities code: 300529 Securities abbreviation: Jianfan Biotechnology Announcement number: 2025-100 Bond code: 123117 Bond abbreviation: Jianfan Convertible Bonds
Jianfan Biotechnology Group Co., Ltd.
Announcement on applying for a comprehensive credit line from the bank
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
Jianfan Biotechnology Group Co., Ltd. (hereinafter referred to as the "Company") held the 38th meeting of the fifth board of directors on December 31, 2025, and reviewed and approved the "Proposal on Applying for a Comprehensive Credit Line from the Bank". Based on the company's business development needs and capital arrangements, the company plans to apply to the bank for a comprehensive credit line of no more than RMB 1.5 billion (including the principal amount, which will be subject to the actual credit line approved by the bank). The validity period of the comprehensive credit line is 12 months from the date of review and approval by the board of directors.
1. The company’s application for credit line from the bank this time
Based on the company's business development needs and capital arrangements, the board of directors agreed that the company and its subsidiaries should apply to the bank for a comprehensive credit line with a total amount not exceeding RMB 1.5 billion, with a credit period of one year. Types of credit include but are not limited to bank acceptance bills, letters of credit, letters of guarantee, standby letters of credit, trade financing, loans, etc. The specific name of the bank and the amount to be applied for are subject to the agreement signed between the company and the relevant bank. The above credit limit is not equal to the actual financing amount of the company. It is based on the actual financing amount between the bank and the company and its subsidiaries. The specific financing amount will be determined based on the actual needs of the company and its subsidiaries. The company's board of directors authorizes the chairman or his authorized representative to sign the above-mentioned legal documents related to this credit extension.
2. The necessity of applying for a bank credit line and its impact on the company
The company's application for comprehensive bank credit this time is necessary for the company's normal operations and business development, and can promote the company's business development. This application for credit line will not have an impact on the company's financial status and operating results this year.
3. Review procedure
This application for comprehensive bank credit has been reviewed and approved by the company at the 38th meeting of the fifth board of directors held on December 31, 2025. According to laws and regulations such as the "Shenzhen Stock Exchange GEM Stock Listing Rules", "Shenzhen Stock Exchange Listed Companies Self-Regulatory Guidelines No. 2 - Standardized Operations of GEM Listed Companies" and the "Articles of Association" and other relevant provisions, this proposal does not need to be submitted to the company's shareholders' meeting for review.
4. Documents for reference
Resolution of the 38th meeting of the company’s fifth board of directors;
Minutes of the 13th meeting of the Audit Committee of the fifth session of the Board of Directors of the company;
Resolution of the seventh special meeting of independent directors of the company’s fifth board of directors in 2025.
Announcement is hereby made.
Board of Directors of Jianfan Biotechnology Group Co., Ltd.
December 31, 2025